When we then examined this approach in vivo, we found that treatment of CML-affected mice with IM alone delayed disease onset compared with the vehicle-treated group, but, as expected, these animals eventually experienced recurrence of BCR-ABL1+ disease after discontinuation of the therapy (Fig. 6d, blue line). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.